Histotype
Brain
Parameter | Information |
---|---|
Strain | NCr Nude |
Implant Type | Cells |
Implant Location | Intracranial |
Time to Staging | 12 days |
Time to Evaluation Size (days) | N/A |
Td | 2.7 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Human
321
Glioblastoma (GBM) patients are known to have a poor prognosis and tumor progression with high mortality and a median survival of only 12-15 months. Currently, anti-GBM therapy includes a multi-modality method involving radiotherapies and surgical removal of the tumor in combination with chemotherapy.1